ArticleESMO open2024

Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.

H Jourdain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.